Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rialto: Expanded Access Blinatumomab in Pediatric Relapsed/Refractory B-precursor ALL
2014-001700-21Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2014
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Primary endpoint: Incidence of treatment-emergent and treatment-related adverse events. Started Sep 2014; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2014-001700-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001700-21.